Research & Innovation - Participant Portal

Health Co-ordination activities

H2020-HCO-2014Sub call of: H2020-HCO-2014-2015
Opening Date 11-12-2013 Deadline Date 15-04-2014 17:00:00 (Brussels local time)
Publication date 11-12-2013 Total Call Budget €40,000,000
Programme Horizon 2020
Status Closed Main Pillar Societal Challenges
OJ reference OJ C 361 of 11 December 2013

Topic: ERA NET rare disease research implementing IRDiRC objectives HCO-10-2014

Specific challenge: Maximising scarce resources and coordinating research efforts are key elements for success in the area of rare diseases, characterised by scattered knowledge and relatively small patient populations. Transnational cooperation and coordination to pool resources and avoid duplication of efforts, while developing common standards and research priorities, is therefore essential. The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to strengthen international collaboration in the area with the aim of delivering 200 new therapies for rare diseases and means to diagnose most of them by the year 2020[1]. An ERA-NET focused on funding research according to IRDiRC objectives and priorities should be an implementation tool for the realisation of the IRDiRC 2020 goals.

 

Scope: Proposals should coordinate national and regional programmes for research on rare diseases by preparing and implementing a transnational call with EU co-funding, resulting in grants to third parties, with a view to implement IRDiRC[2] objectives and identified priorities. This call should aim at furthering the understanding of disease mechanisms and natural history of rare diseases with the objective to develop new diagnostic tools and treatments. Selected proposals should adhere to the policies and guidelines of IRDiRC.

 

Proposals should be complementary with other funding programmes and activities on European and international level.

 

Proposals should demonstrate the expected impact on national and transnational programmes and IRDiRC objectives as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this.

 

Proposals should also aim at implementing other joint activities including training and additional joint calls without EU co-funding. 

 

The Commission considers that proposals requesting a contribution from the EU of a minimum of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact:

  • In line with the Union’s strategy for international cooperation in research and innovation[3], the project will contribute to reaching the overall goals of IRDiRC;
  • Deepened and extended coordination of national and transnational research in the field of rare diseases resulting in a substantial contribution to the overall goals of IRDiRC;
  • Streamlined national/regional and international practices in organising research funding;
  • Increased interoperability of national research programmes;
  • Increased sharing of data and knowledge;
  • Increased networking of infrastructures and databases.

 

Type of action: ERA-NET Co-fund


[1] www.irdirc.org

[2] The IRDiRC policies and guidelines document is available on: http://www.irdirc.org/?page_id=12

[3] COM(2012)497

Please read carefully all provisions below before the preparation of your application.

1. List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in projects supported under all topics in calls under the Societal Challenge ‘Health, demographic change and well-being’.

2. Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme

3. Evaluation

3.1 Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme

3.2 Guide to the submission and evaluation process

4. Proposal page limits and layout: Please refer to Part B of the standard proposal template.

5. Indicative timetable for evaluation and grant agreement:
Information on the outcome of one-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.

6. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:

ERANET Cofund:

Specific provisions and funding rates
Standard proposal template (administrative forms and structure of technical annex)
Standard evaluation form
Annotated Model Grant Agreement
 

7. Additional provisions:

Horizon 2020 budget flexibility

Classified information


8. Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.

 

Additional documents

You can download the same documents as one zip file from the call page

  • Legal basis - Specific Programme H2020 en
  • WP H2020 - 1. Introduction en
  • WP H2020 - 8. Health, demographic change and wellbeing en
  • Legal basis - Framework Programme H2020 en
  • Legal basis - Rules for Participation en
  • WP H2020 - 19. General Annexes en
  • FAQ en
  • A guide to ICT-related activities in WP2014-15 en
  • Information document about GloPID-R - draft charter en

No submission system is open for this topic.